Small & Mid-Cap Healthcare Preview

About Viking Therapeutics

Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. The company's lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trials to treat patients with biopsy-confirmed non-alcoholic steatohepatitis, as well as NAFLD.

It also develops VK5211, an orally available non-steroidal selective androgen receptor modulator that is in Phase II clinical trials for the treatment of patients recovering from non-elective hip fracture surgery; VK0612, an orally available Phase IIb-ready drug candidate for type 2 diabetes; VK2735, a novel dual agonist of the glucagon-like peptide, which is in Phase 1 SAD/MAD clinical trial, and VK0214, an orally available tissue and receptor-subtype selective agonist of the TRß for X-linked adrenoleukodystrophy. The company was incorporated in 2012 and is headquartered in San Diego, California.

VKTX operates in the Manufacturing | Pharmaceutical Products | headquartered in SAN DIEGO, California | approximately 20 employees | led by CEO Brian Lian.

Sector Report: Small & Mid-Cap Healthcare
Date: January 26, 2026
Analyst: Priyum Daga

Finding Value in the "Forgotten" Middle

Executive Summary

The healthcare sector has quietly split in two. Capital keeps flowing heavily into the mega-cap pharmaceutical names and the dominant MedTech incumbents, while large swaths of the small and mid-cap universe continue to trade at depressed levels after an extended period of derating.

This bifurcation has produced one of those infrequent opportunities: a group of smaller companies where fundamentals are visibly improving and near-term catalysts are clear, yet the market continues to price them as though capital remains scarce and strategic interest is dormant.

Against that backdrop, we’ve selected ten small and mid-cap healthcare names that stand out for the combination of attractive valuation, strategic positioning, and tangible upcoming catalysts. These are ranked explicitly by our view of valuation upside and level of conviction and not simply by headline return potential or narrative momentum.

The 2026 Sector Watchlist

Detailed investment models and catalysts for Stocks #2–#10 are available below for free subscribers.

1. Viking Therapeutics (VKTX): The Pure-Play Obesity Bet

The Thesis:

We don’t assign Economic Moats to clinical-stage biotech companies. Viking stands out, however, as a differentiated pure-play obesity exposure with rising strategic relevance. Lead asset VK2735 delivered 12.2% mean weight loss over 13 weeks in Phase 2, comparable to approved GLP-1s. Its dual GLP-1/GIP mechanism could provide clinical and commercial differentiation down the line.

Phase 3 VANQUISH-1 enrollment is complete; VANQUISH-2 should wrap in early 2026. Cash reserves are sufficient to reach a potential 2027 NDA filing, minimizing near-term financing risk. Recent obesity M&A has created a valuation benchmark for late-stage assets, and Viking trades at a clear discount to those levels.

Bulls Say

VK2735’s efficacy positions Viking as a credible challenger in the fast-expanding obesity market either as an independent player or acquisition target.

Bears Say

The story remains binary. Oral formulation tolerability issues plus Phase 3 risks could cause significant capital impairment on disappointing data.

2. Integra LifeSciences (IART) – The Surgical Turnaround Story

The Thesis:

Integra, a diversified surgical device company, has been hit hard by two years of operational disruptions and supply-chain problems. Current pricing implies permanent impairment we view as overly pessimistic given core franchise strength. Neurosurgery and tissue regeneration benefit from high surgeon switching costs, supporting the Narrow Moat rating. Recent FDA clearance for CUSA Clarity in cardiovascular procedures expands its addressable market.

Management’s cost-reset program targets $20–30 million in annual savings, with free cash flow turning sustainably positive by 2027. Cost discipline and franchise resilience should drive margin and cash-flow recovery.

Bulls Say

Operational stabilization and incremental margin gains could trigger a meaningful re-rating from current depressed multiples.

Bears Say

Execution risk is still elevated, and any further delays in fixing the supply-chain issues could keep investor skepticism alive for longer than anticipated.

3. Inspire Medical Systems (INSP) – The Sleep Apnea Innovation Leader

The Thesis:

The market discounts Inspire on fears that GLP-1 drugs will structurally shrink OSA prevalence which is an overreaction in our view. OSA is primarily anatomical; GLP-1s may ease symptoms in some high-BMI patients but don’t address root causes for most. Inspire is the only FDA-approved implantable hypoglossal nerve stimulation therapy for moderate-to-severe OSA in CPAP-intolerant patients. Penetration remains <3% of 4M eligible U.S. patients ($10B addressable market). Over 100,000 global implants and >350 peer-reviewed publications, plus surgeon learning curves, create durable barriers and a clinical moat.

The anticipated 2026 CMS reimbursement step-up (~$45k hospital / $42.4k ASC) was reversed in January 2026, resetting to 2025 levels and adding near-term uncertainty. Inspire V’s ~20% shorter implant time improves throughput and site economics. Strong real-world adherence (>6 hours/night vs. typical CPAP) supports volume reacceleration post-transition. Reimbursement clarity is delayed, not eliminated.

Bulls Say

Inspire V boosts procedural efficiency for higher case volumes without added infrastructure. Superior adherence drives strong outcomes (+0.177 utility index). Reimbursement resolution should unlock double-digit growth across hospitals and ASCs.

Bears Say

2026 guidance of 10–11% growth reflects IV-to-V inventory transition. GLP-1s may delay intervention in some patients. The CMS reversal heightens execution risk and pressures sentiment at 46–55x forward P/E.

4. Tandem Diabetes (TNDM) – The Automated Insulin Delivery Play

The Thesis:

Tandem trades at distressed levels after years of share loss to Insulet’s Omnipod and Medicare reimbursement uncertainty and is down ~71% from its 52-week high, signaling fears of obsolescence we consider excessive. It retains a leading position in insulin pumps with a large Type 1 installed base and recurring infusion-set revenue.

Underappreciated catalysts include expanded Abbott FreeStyle Libre CGM integration (broadening addressability) and the late-2025 limited launch of Tandem Mobi, which addresses bulk/visibility complaints while preserving the Control-IQ algorithm. Trading below cash-adjusted book value implies near-irrelevance which is an unlikely scenario given the roadmap and ecosystem integration.

Bulls Say

Mobi closes the form-factor gap vs. patch pumps while retaining software advantage. Libre integration expands the customer pool. At these levels, Tandem is a logical acquisition target for MedTech players lacking insulin delivery.

Bears Say

The AID market is fiercely competitive where Insulet dominates tubeless and Medtronic has scale. If Mobi fails to gain traction in 2026, the path to sustained profitability narrows sharply.

5. Repligen (RGEN) – The Bioprocessing Infrastructure Bet

The Thesis:

Repligen is a high-quality “picks and shovels” supplier of chromatography resins, filtration, and analytics deeply embedded in biologics/gene therapy manufacturing. Narrow Moat stems from regulatory entrenchment and high switching cost. The recent pullback reflects transient inventory destocking, not demand weakness: Q3 2025 showed 18% organic revenue growth and >20% YoY order increase. U.S. biopharma reshoring is a durable tailwind where >$480B in announced domestic investment since 2025 (including $27B from Eli Lilly) will drive equipment demand as capacity comes online in 2026–2027. As a pure-play in a ~$140B market growing ~14.5% CAGR (UBS), the premium valuation remains justified.

Bulls Say

Repligen dominates niches in gene therapy purification and continuous manufacturing. New chromatography resins and bead technology improve viral vector throughput and stability, easing key bottlenecks. It is strongly positioned in the ~$2.8B gene therapy purification TAM.

Bears Say

Biopharma capex is cyclical and interest-rate sensitive. Shifts to new modalities could dilute near-term growth; ATF filtration competition may pressure margins if pricing intensifies.

6. Hims & Hers (HIMS) – The Consumerization of Healthcare

The Thesis:

The key driver is the mid-2025 Zava acquisition, which expanded into the UK/EU, broadened TAM, and reduced U.S. regulatory dependence.

HIMS is proving DTC telehealth can scale profitably. The platform spans hair loss, sexual health, mental health, dermatology, and weight management (compounded GLP-1s at $245–$350/month vs. >$1,000 branded). Already cash-flow positive and profitable, it is tracking toward ~$2B revenue by 2026 from near-zero five years ago. HIMS Labs (120+ biomarker testing) adds recurring high-margin revenue. No Moat assigned due to low entry barriers, but brand equity, subscription stickiness, and rising power-user engagement create growing defensibility as healthcare consumerizes.

Bulls Say

Scale plus profitability validates unit economics. Zava adds billions to TAM and diversifies regulatory risk. Personalized weight loss, dermatology, and diagnostics offer a long runway with improving margin mix.

Bears Say

Regulatory risk looms largest FDA scrutiny of compounded GLP-1s could eliminate a meaningful revenue stream. Incumbents like CVS/Walgreens entering telehealth may raise acquisition costs and hurt retention.

7. Lantheus (LNTH) – The Diagnostic Imaging Play

The Thesis:

Lantheus efficiently monetizes radiopharmaceuticals via focused diagnostic imaging and targeted oncology. Pylarify is now standard-of-care in prostate cancer imaging; Definity provides steady recurring revenue. Q3 2025 revenue was $384M (+1.4% YoY), with Pylarify at $240.6M (volumes up despite price/mix pressure). Core execution remains strong. The 2026 theranostics expansion pairing diagnostics with targeted radionuclide therapies meaningfully enlarges TAM (potentially billions) while leveraging existing infrastructure. Management targets >70% gross margins by year-end 2026 via pricing power and leverage. Narrow Moat reflects defensible niche, regulatory expertise, and entrenched relationships in nuclear medicine/oncology.

Bulls Say

Theranostics is a structural oncology shift. Lantheus enters with distribution, regulatory know-how, and profitable diagnostics which are advantages few competitors match for speed and scale.

Bears Say

Large pharma (e.g., Novartis) is aggressively investing in radioligands, which could crowd the field and compress margins. New theranostic approval timelines introduce uncertainty.

8. Jazz Pharmaceuticals (JAZZ) – The Oncology Pipeline Catalyst

The Thesis:

Jazz is pivoting from narcolepsy (where generics erode Xyrem/Xywav) toward diversified oncology. The market undervalues the pipeline, led by zanidatumab (Ziihera), a bispecific HER2 antibody with blockbuster potential.

HERIZON-GEA-01 Phase 3 top-line (Nov 2025) met dual PFS endpoints; OS was statistically significant in the Ziihera + tislelizumab + chemo arm (strong trend in chemo arm; second interim mid-2026). sBLA planned H1 2026 for potential 2026 approval. Peak sales estimates >$1B, with optionality in breast and biliary tract cancers. Zepzelca adds upside as sNDA filed for SCLC combo after significant PFS/OS gains; Zepzelca + atezolizumab approved October 2025 for first-line maintenance in extensive-stage SCLC. Strong cash flow supports deleveraging and pipeline funding.

Bulls Say

Zanidatumab’s GEA survival data far exceeds historical benchmarks, supporting blockbuster potential not fully priced in. Multiple near-term oncology catalysts offer asymmetric upside; legacy cash flow funds execution.

Bears Say

Narcolepsy biosimilar erosion pressures near-term revenue, increasing reliance on pipeline delivery. Acquisition-related leverage heightens sensitivity to clinical/regulatory setbacks.

9. Haemonetics (HAE) – The Blood Management Leader

The Thesis:

Haemonetics operates in an effective oligopoly for plasma collection devices like mission-critical equipment and disposables under long-term contracts. Narrow Moat arises from high switching costs, regulatory complexity, and operational disruption of vendor changes.

Post-pandemic plasma market is recovering with rising collection volumes and utilization. Hospital blood management and hemostasis segments (automated collection, cell salvage, transfusion software) are driving margin expansion which is evident in Q3 2025 despite modest revenue pressure. Structural drivers include aging demographics, chronic shortages, and growing plasma-derived therapy demand. At ~12.6x forward P/E, it trades at a discount to MedTech peers despite recurring consumables revenue and strong free cash flow.

Bulls Say

Plasma volumes offer secular growth from rising immunoglobulin and plasma-derived therapy demand. Haemonetics’ scale and installed base position it to gain disproportionately as the market normalizes and consolidates.

Bears Say

Revenue has historically been uneven, especially in hospitals (procedure-volume sensitive). Customer concentration (CSL Plasma in particular) creates bargaining-power risk.

10. Arcellx (ACLX) – The Next-Generation CAR-T Play

The Thesis:

Arcellx targets CAR-T’s core limitation: toxicity. Lead asset anito-cel, a next-gen CAR-T for relapsed/refractory multiple myeloma, uses proprietary D-Domain platform to reduce CRS and neurotoxicity.

ASH 2025 updated data showed 97% ORR with markedly lower neurotoxicity vs. existing CAR-Ts which if replicated registrational, eligibility could expand materially. iMMagine-1 Phase 2 complete; pre-BLA FDA meeting held; manufacturing transferred to Kite. 2026 commercial launch remains target. Stock appears fairly valued to modestly undervalued with high promise offset by intense competition and binary execution risk.

Bulls Say

Superior safety label could position anito-cel as preferred second-line CAR-T. Lower toxicity reduces hospitalizations, broadens eligibility, and improves payer acceptance. Kite manufacturing de-risks commercialization and provides infrastructure most small biotechs lack.

Bears Say

Multiple myeloma CAR-T is highly competitive where J&J’s Carvykti sets a high bar. Manufacturing issues, safety signals, or regulatory delays would face severe punishment at ~9x price-to-book.

The Bottom Line

Healthcare is in a generational shift, and while mega-caps dominate attention, the best alpha lies in small and mid-cap names early in their commercial cycles. These ten stocks combine defensible positions, clear catalysts, and skeptical valuations. The road to 2026 will be volatile, but for disciplined investors, healthcare remains a contrarian opportunity to compound capital at 30-50% annually.